Thieu William, Tilki Derya, de Vere White Ralph, Evans Christopher P
Department of Urology, University of California, Davis, Medical Center, Sacramento, CA, USA.
Urol Oncol. 2014 Jul;32(5):517-523. doi: 10.1016/j.urolonc.2013.11.004.
Castration-resistant prostate cancer (CRPC) has a historically low median survival rate, but recent advances and discoveries in microRNAs (miRNAs) have opened the potential for new prognostication modalities to enhance therapeutic success. As new chemotherapies and immunotherapies are developed, there is an increasing need for precision and stratification of CRPC to allow for optimization and personalization of therapy.
A systematic literature review was conducted via electronic database resulting in the selection of 42 articles based on title, abstract, study format, and content by a consensus of all participating authors. Most selected articles were published between 2002 and 2013. In this review, we discuss the robustness of miRNAs as a biomarker platform, miRNAs associated with prostate cancer, and recent discoveries of miRNA associations with CRPC.
The associations discovered have been of interest owing to the ability to differentiate between CRPC and localized prostate cancer. With the evaluation of multiple miRNAs, it is possible to provide a profile regarding tumor characteristics. Furthermore, actions of miRNAs on CRPC tumor cells have the ability to suppress metastatic phenotypes.
miRNAs may have a growing role in CRPC prognostication and may potentially transform into a therapeutic potential.
去势抵抗性前列腺癌（CRPC）的历史中位生存率较低，但近年来微小RNA（miRNA）领域的进展和发现为新的预后评估方式带来了可能，有望提高治疗成功率。随着新的化疗和免疫疗法的不断研发，对CRPC进行精准分类和分层的需求日益增加，以便实现治疗的优化和个性化。
通过电子数据库进行系统的文献综述，所有参与作者共同根据标题、摘要、研究形式和内容筛选出42篇文章。大多数入选文章发表于2002年至2013年之间。在本综述中，我们讨论了miRNA作为生物标志物平台的稳健性、与前列腺癌相关的miRNA以及最近发现的miRNA与CRPC的关联。
所发现的关联因其能够区分CRPC和局限性前列腺癌而备受关注。通过评估多种miRNA，可以提供有关肿瘤特征的概况。此外，miRNA对CRPC肿瘤细胞的作用具有抑制转移表型的能力。
miRNA在CRPC预后评估中可能发挥越来越重要的作用，并有可能转化为一种治疗潜力。
